GO:0033209 tumor necrosis factor-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033209 describes the molecular signaling cascade triggered when tumor necrosis factor (TNF) binds to its cell-surface receptors, culminating in regulation of downstream cellular processes such as transcription, apoptosis, or necroptosis [1,6].
• TNF-mediated signaling bifurcates into survival/inflammatory arms (NF-kB, JNK) and death arms (apoptosis, necroptosis), with the outcome determined by receptor context and cellular state [2,6].
• Key signaling nodes include TNF receptor-associated factors (TRAFs), TANK, and downstream kinases that activate NF-kB and c-Jun N-terminal kinase (JNK) [7,8].
• Dysregulated TNF signaling is implicated in cancer, cardiovascular disease, and inflammatory pathologies, making it a major therapeutic target [1,2,4].
• Alternative splicing and crosstalk with other pathways (e.g., BMP/Smad, Akt) fine-tune TNF-mediated responses [3,4,5].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of TNF pathway components in disease-relevant cell types.
Description
Tumor necrosis factor (TNF) is a pleiotropic cytokine that orchestrates diverse cellular outcomes, from inflammation and survival to programmed cell death. The Gene Ontology term GO:0033209, tumor necrosis factor-mediated signaling pathway, captures the series of molecular signals initiated by TNF binding to its receptor on the cell surface and ending with regulation of a downstream cellular process, such as transcription [1,6]. This pathway is fundamental to immune defense, tissue homeostasis, and pathogenesis of numerous diseases. Researchers study GO:0033209 to understand how a single ligand-receptor interaction can produce context-dependent responses, including NF-kB activation, JNK signaling, apoptosis, and necroptosis [2,6,7]. The pathway's complexity arises from post-translational modifications, scaffolding proteins, and crosstalk with other signaling cascades [3,4,5]. Because dysregulated TNF signaling underlies cancer, cardiovascular disorders, and inflammatory diseases, it remains a focal point for therapeutic development [1,2,4]. This article provides a research-grade overview of GO:0033209, integrating authoritative QuickGO annotations with verified PubMed literature to support experimental design and generative-AI retrieval.
tumor necrosis factor-mediated signaling pathway At A Glance
| GO ID | GO:0033209 |
|---|---|
| GO term | tumor necrosis factor-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | adipocytokine signaling pathway; TNF-alpha-mediated signaling pathway; tumor necrosis factor alpha-mediated signaling pathway; tumor necrosis factor-mediated signalling pathway |
| Major function | Transduces TNF ligand binding into downstream cellular responses including transcription, apoptosis, and necroptosis |
| Key receptors | TNF receptor superfamily members (e.g., TNFR1, TNFR2) |
| Major downstream pathways | NF-kB, JNK/stress-activated protein kinase, apoptosis, necroptosis |
| Cellular context | Immune cells, cancer cells, cardiomyocytes, oligodendrocytes, and other cell types |
| Disease relevance | Cancer, cardiovascular disease, inflammation, neurodegeneration |
What Is GO:0033209?
GO:0033209, tumor necrosis factor-mediated signaling pathway, is defined as the series of molecular signals initiated by tumor necrosis factor binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription. This biological process encompasses receptor engagement, adaptor recruitment, kinase activation, and transcriptional or apoptotic outcomes. Synonyms include adipocytokine signaling pathway, TNF-alpha-mediated signaling pathway, and tumor necrosis factor alpha-mediated signaling pathway.
Why Is tumor necrosis factor-mediated signaling pathway Important in Cell Biology?
GO:0033209 is critically important because TNF-mediated signaling governs fundamental decisions between cell survival, inflammation, and death, and its dysregulation contributes to a wide spectrum of human diseases. Understanding this pathway at molecular resolution is essential for developing targeted therapies that can selectively modulate TNF responses in cancer, autoimmune conditions, and tissue injury [1,2,4,6].
• Controls NF-kB activation, a master regulator of inflammation and survival [7,8].
• Activates JNK/stress-activated protein kinase pathways through TRAF and TANK-dependent mechanisms [7,8].
• Determines cell fate decisions between apoptosis and necroptosis in cancer cells [2,6].
• Plays a central role in cardiac repair after myocardial infarction.
• Regulated by alternative splicing, adding another layer of complexity in inflammation.
• Crosstalks with BMP/Smad signaling to suppress TNF-mediated apoptosis.
• Modulated by neurotrophic factors such as NGF via Akt signaling in oligodendrocytes.
• Implicated in inflammatory diseases and cancer progression [2,4].
• Serves as a target for biologic therapies (e.g., anti-TNF agents).
• Provides a paradigm for understanding how a single ligand can elicit context-dependent outcomes.
What Happens During tumor necrosis factor-mediated signaling pathway?
Receptor Engagement and Adaptor Recruitment
In simple terms: TNF binds to its receptor on the cell surface, triggering the assembly of a signaling complex inside the cell.
The pathway begins when tumor necrosis factor (TNF) binds to its cognate receptors, primarily TNFR1 and TNFR2, on the plasma membrane. This binding induces receptor trimerization and recruitment of adaptor proteins such as TRADD and TRAF family members. TRAF proteins, including TRAF2, serve as key hubs that link receptor activation to downstream kinases [7,8]. The zinc ring finger domain of TRAF proteins is required for NF-kB activation but dispensable for JNK signaling, indicating divergent structural requirements. TANK potentiates TRAF-mediated JNK/stress-activated protein kinase activation through the germinal center kinase pathway.
NF-kB Activation
In simple terms: A major outcome of TNF signaling is turning on NF-kB, which drives expression of genes that promote survival and inflammation.
Following receptor engagement, the IKK complex is activated, leading to phosphorylation and degradation of IkB, allowing NF-kB to translocate to the nucleus and regulate transcription. This arm of the pathway is critical for inflammatory responses and cell survival. An intact zinc ring finger of TRAF proteins is required for NF-kB activation, as demonstrated by mutagenesis studies. TANK also contributes to NF-kB activation through TRAF-mediated mechanisms.
JNK/Stress-Activated Protein Kinase Activation
In simple terms: TNF signaling can also activate stress kinases that modify gene expression and cell fate.
In parallel to NF-kB, TNF receptor-associated factors activate the c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) cascade. TANK potentiates this activation through the germinal center kinase pathway. Unlike NF-kB activation, JNK signaling does not require the zinc ring finger of TRAF proteins. This branch influences apoptosis, differentiation, and inflammatory gene expression.
Cell Death: Apoptosis and Necroptosis
In simple terms: Depending on context, TNF signaling can instruct cells to die via apoptosis or a lytic form of cell death called necroptosis.
TNF-mediated cell death is a critical outcome in cancer and tissue injury. The decision between apoptosis and necroptosis is regulated by the availability of caspase-8 and RIPK kinases [2,6]. In cancer cells, TRAIL and TNF can both induce necroptosis, but with differences in signaling components. The balance between survival (NF-kB) and death (JNK, caspases) determines the cellular response to TNF.
Crosstalk and Modulation by Other Pathways
In simple terms: Other signaling pathways can interfere with TNF signaling, altering the final outcome.
TNF signaling is modulated by crosstalk with other pathways. For example, bone morphogenetic protein (BMP)/Smad signaling suppresses TNF-mediated apoptosis in a NF-kB-independent manner. Nerve growth factor (NGF) protects oligodendrocytes from TNF-alpha-induced injury through Akt-mediated signaling. Additionally, alternative splicing regulates components of the TNF-mediated inflammatory response, adding another layer of control.
Key Genes Involved in GO:0033209 tumor necrosis factor-mediated signaling pathway
The following genes and proteins are central to the tumor necrosis factor-mediated signaling pathway (GO:0033209) and are frequently studied using CRISPR-based models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNF | Ligand that initiates the pathway | Target for anti-inflammatory therapies; knockout models to study loss of signaling |
| TNFRSF1A | TNFR1 receptor for TNF | Mediates most inflammatory and apoptotic effects; point mutations linked to autoinflammatory syndromes |
| TNFRSF1B | TNFR2 receptor for TNF | Modulates immune cell activation and survival; knock-in models for receptor-specific signaling |
| TRADD | Adaptor protein recruited to TNFR1 | Scaffold for downstream complex assembly; knockout reduces NF-kB and apoptosis |
| TRAF2 | E3 ubiquitin ligase; activates NF-kB and JNK | Zinc ring finger required for NF-kB but not JNK; knockout impairs signaling |
| TRAF5 | TRAF family member | Contributes to NF-kB activation; redundancy with TRAF2 |
| TANK | Potentiates TRAF-mediated JNK activation | Knockout or overexpression to dissect JNK-specific outcomes |
| RIPK1 | Kinase central to necroptosis and NF-kB | Point mutations to separate kinase-dependent and scaffold functions |
| RIPK3 | Kinase required for necroptosis | Knockout blocks necroptosis; key for cancer cell death studies |
| MLKL | Executioner of necroptosis | Knockout or knock-in of phospho-mimetic mutants |
| CASP8 | Initiator caspase for apoptosis | Knockout switches TNF response from apoptosis to necroptosis |
| NFKB1 | Transcription factor subunit | Knockout reduces inflammatory gene expression |
| RELA | Transcription factor subunit | Overexpression enhances NF-kB-driven survival |
| MAP3K7 | TAK1 kinase upstream of NF-kB and JNK | Conditional knockout to study kinase-dependent effects |
| MAPK8 | JNK1 kinase | Knockout to assess stress kinase contribution |
| BIRC2 | cIAP1, ubiquitin ligase | Knockout sensitizes cells to TNF-induced death |
| BIRC3 | cIAP2, ubiquitin ligase | Similar to BIRC2; double knockout enhances cell death |
| SMAD1 | BMP signaling effector | Overexpression suppresses TNF-mediated apoptosis |
How Is tumor necrosis factor-mediated signaling pathway Regulated?
The tumor necrosis factor-mediated signaling pathway is tightly regulated at multiple levels. Post-translational modifications, including ubiquitination and phosphorylation, control the assembly and stability of receptor-proximal complexes [7,8]. Alternative splicing generates variant isoforms of pathway components, influencing inflammatory outcomes. Crosstalk with other signaling cascades, such as BMP/Smad and Akt pathways, modulates the strength and duration of TNF responses [3,5]. Additionally, the balance between NF-kB-mediated survival and JNK-mediated death signaling determines cell fate.
tumor necrosis factor-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNF | Inflammatory diseases, cancer | Knockout mice; overexpression in cell lines |
| TNFRSF1A | Autoinflammatory syndromes | Point mutation knock-in (e.g., TRAPS mutations) |
| RIPK3 | Cancer cell death resistance | Knockout in cancer cell lines; necroptosis assays |
| CASP8 | Apoptosis dysregulation | Knockout to switch to necroptosis |
| SMAD1 | TNF resistance in cancer | Overexpression to suppress apoptosis |
Cancer
TNF-mediated signaling plays a dual role in cancer, promoting survival and inflammation in some contexts while inducing cell death in others. Necroptotic signaling downstream of TNF is a critical mechanism for eliminating cancer cells, and differences between TRAIL- and TNF-mediated necroptosis have been characterized in cancer cell lines. Targeting this pathway is a promising therapeutic strategy.
Cardiovascular Disease
TNF signaling is implicated in cardiac repair after myocardial infarction. Cellular effectors and molecular mechanisms of repair involve inflammatory cytokines including TNF, and modulating this pathway may offer therapeutic opportunities for heart failure.
Inflammatory and Autoimmune Diseases
Dysregulated TNF signaling drives chronic inflammation. Alternative splicing of genes in the TNF-mediated inflammatory pathway contributes to disease heterogeneity, and understanding these mechanisms can inform new treatments.
Neurodegeneration
TNF-alpha induces injury in oligodendrocytes, which can be protected by neurotrophic factors such as NGF through Akt-mediated signaling. This highlights the relevance of TNF signaling in demyelinating diseases and neurodegeneration.
From tumor necrosis factor-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TRAF2 impair NF-kB activation? | TRAF2 knockout cell line |
| Does the zinc ring finger of TRAF2 specifically mediate NF-kB but not JNK? | Point mutation (zinc ring finger mutant) knock-in |
| Can TANK overexpression enhance JNK activation? | TANK overexpression stable cell line |
| Does NGF protect oligodendrocytes from TNF-induced death? | Akt knockout or overexpression in oligodendrocytes |
| Does BMP/Smad signaling suppress TNF-mediated apoptosis? | SMAD1 overexpression or knockout |
| What is the role of alternative splicing in TNF inflammation? | CRISPR-mediated splice-site mutation |
How to Study the tumor necrosis factor-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify NF-kB target genes and splicing variants |
| Phosphoproteomics | Kinase activation and signaling nodes | Map TNF-induced phosphorylation events |
| Immunoblotting | Protein levels and modifications | Detect IkB degradation, JNK phosphorylation [7,8] |
| Caspase activity assay | Apoptosis execution | Measure TNF-induced apoptosis |
| Necroptosis assay (phospho-MLKL) | Necroptotic cell death | Assess RIPK3/MLKL-dependent death |
| NF-kB luciferase reporter | NF-kB transcriptional activity | Screen for pathway modulators |
| Co-immunoprecipitation | Protein-protein interactions | Study TRAF-TANK complex formation |
| CRISPR screening | Gene essentiality in TNF response | Identify novel regulators of TNF signaling |
Transcriptomic Analysis (RNA-seq)
RNA sequencing measures global changes in gene expression following TNF stimulation, revealing transcriptional outputs of NF-kB and other transcription factors. It can also detect alternative splicing events regulated by TNF signaling.
Proteomic and Phosphoproteomic Profiling
Mass spectrometry-based proteomics identifies protein complexes and post-translational modifications in the TNF signaling cascade, such as ubiquitination of TRAFs and phosphorylation of JNK [7,8].
Cell Death Assays
Apoptosis and necroptosis are measured using viability assays, caspase activity assays, and phospho-MLKL immunoblotting. These methods distinguish between different modes of TNF-induced cell death [2,6].
Imaging and Reporter Assays
Live-cell imaging and luciferase reporter assays for NF-kB or JNK activity allow real-time monitoring of pathway dynamics in response to TNF. Fluorescently tagged proteins can track complex assembly.
How CRISPR Can Be Used to Study GO:0033209 tumor necrosis factor-mediated signaling pathway
Knockout
CRISPR knockout of key TNF pathway genes (e.g., TRAF2, TANK, RIPK3) enables loss-of-function studies to determine their necessity in NF-kB activation, JNK signaling, or cell death. For example, TRAF2 knockout abolishes NF-kB activation.
Point Mutation
Point mutations can dissect domain-specific functions. Introducing a mutation in the zinc ring finger of TRAF2 disrupts NF-kB activation while leaving JNK signaling intact, as shown by mutagenesis. CRISPR-mediated point mutation knock-in allows such precise editing in endogenous loci.
Knock-in
Knock-in of tagged proteins (e.g., GFP-TRAF2) or disease-associated mutations (e.g., TNFR1 variants) facilitates real-time imaging and functional studies. Knock-in models can also express phospho-mimetic or phospho-deficient mutants of signaling kinases.
Overexpression
Overexpression of pathway components such as TANK or SMAD1 can potentiate or suppress TNF signaling. TANK overexpression enhances JNK activation, while SMAD1 overexpression suppresses TNF-mediated apoptosis. These models help establish sufficiency.
How EDITGENE Supports tumor necrosis factor-mediated signaling pathway Research
Researchers studying tumor necrosis factor-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway outcomes such as NF-kB activation, JNK signaling, apoptosis, or necroptosis. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for tumor necrosis factor-mediated signaling pathway research.
Frequently Asked Questions About tumor necrosis factor-mediated signaling pathway
What is GO:0033209?
GO:0033209 is the Gene Ontology term for tumor necrosis factor-mediated signaling pathway, defined as the series of molecular signals initiated by TNF binding to its receptor and ending with regulation of a downstream cellular process, such as transcription.
What genes are involved in tumor necrosis factor-mediated signaling pathway?
Key genes include TNF, TNFRSF1A, TNFRSF1B, TRADD, TRAF2, TRAF5, TANK, RIPK1, RIPK3, MLKL, CASP8, NFKB1, RELA, MAP3K7, MAPK8, BIRC2, BIRC3, and SMAD1 [3,7,8].
What are the main outcomes of TNF signaling?
TNF signaling can lead to NF-kB activation, JNK/stress-activated protein kinase activation, apoptosis, or necroptosis, depending on cellular context [2,6,7].
How is TNF-mediated signaling regulated?
It is regulated by post-translational modifications, alternative splicing, and crosstalk with other pathways such as BMP/Smad and Akt [3,4,5,8].
What diseases are associated with dysregulated TNF signaling?
Dysregulated TNF signaling is associated with cancer, cardiovascular disease, inflammatory and autoimmune diseases, and neurodegeneration [1,2,4,5].
What is the difference between TNF-mediated apoptosis and necroptosis?
Apoptosis is caspase-dependent and non-lytic, while necroptosis is caspase-independent and lytic, relying on RIPK3 and MLKL [2,6].
How can CRISPR be used to study TNF signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of gene function in TNF pathway outcomes [3,7,8].
What methods are used to study TNF-mediated signaling?
Common methods include RNA-seq, phosphoproteomics, immunoblotting, caspase activity assays, necroptosis assays, luciferase reporters, and co-immunoprecipitation [2,4,6,7,8].
What is the role of TANK in TNF signaling?
TANK potentiates TRAF-mediated JNK/stress-activated protein kinase activation through the germinal center kinase pathway.
Does the zinc ring finger of TRAF2 matter for signaling?
Yes, an intact zinc ring finger is required for TRAF-mediated NF-kB activation but is dispensable for JNK signaling.
Conclusion
GO:0033209, tumor necrosis factor-mediated signaling pathway, is a central biological process that translates TNF receptor engagement into diverse cellular outcomes, including inflammation, survival, apoptosis, and necroptosis. Its dysregulation is implicated in cancer, cardiovascular disease, and inflammatory disorders, making it a prime target for therapeutic intervention. CRISPR-based models and multi-omics methods provide powerful tools to dissect the molecular mechanisms and identify novel drug targets. EDITGENE offers comprehensive services to support these research endeavors.
References
- 1. Hilgendorf I et al.. 2024. Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities.. Circ Res 134(12):1718-1751 PMID: 38843294
- 2. Sosna J et al.. 2016. Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells.. Mol Cell Biol 36(20):2626-44 PMID: 27528614
- 3. Chen S et al.. 2001. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappaB-independent bone morphogenetic protein/Smad signaling.. J Biol Chem 276(42):39259-63 PMID: 11500509
- 4. López-Urrutia E et al.. 2017. Alternative splicing regulation in tumor necrosis factor-mediated inflammation.. Oncol Lett 14(5):5114-5120 PMID: 29113151
- 5. Takano R et al.. 2000. Nerve growth factor protects oligodendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms.. J Biol Chem 275(21):16360-5 PMID: 10748222
- 6. Van Herreweghe F et al.. 2010. Tumor necrosis factor-mediated cell death: to break or to burst, that's the question.. Cell Mol Life Sci 67(10):1567-79 PMID: 20198502
- 7. Chin AI et al.. 1999. TANK potentiates tumor necrosis factor receptor-associated factor-mediated c-Jun N-terminal kinase/stress-activated protein kinase activation through the germinal center kinase pathway.. Mol Cell Biol 19(10):6665-72 PMID: 10490605
- 8. Dadgostar H et al.. 1998. An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappaB activation but is dispensable for c-Jun N-terminal kinase signaling.. J Biol Chem 273(38):24775-80 PMID: 9733779
